Zimmer Biomet, OneStep Collaborate to Provide Enhanced Mobility Data to Patients and Surgeons to Help Improve Joint Procedure Recovery

OneStep’s Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet’s mymobility^® Care Management Platform to Further Enhance Recovery Monitoring

WARSAW, Ind., Dec. 16, 2025 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and mobility intelligence platform, today announced an exclusive collaboration agreement aimed at delivering the orthopedic industry’s most comprehensive set of mobility data to further empower surgeons to track recovery progress more effectively following joint replacement surgery and enable patients to play an active role in their recovery.

The collaboration will use OneStep’s gait and mobility analytics that are captured on both iPhone^® and Android smartphones and integrate the data directly into Zimmer Biomet’s mymobility^® Care Management Platform for orthopedic surgery patients. Users of mymobility have access to daily, objective insights across their joint replacement journey, from surgical preparation through recovery using only their smartphone. The integration enables remote assessment of gait and functional mobility powered by OneStep’s clinically validated technology, delivered seamlessly through the mymobility app.

“This partnership represents a significant step forward in continuing to connect the dots between surgical innovation, patient engagement and functional outcomes,” said Robert Kraal, vice president and general manager of Connected Health at Zimmer Biomet. “By incorporating OneStep’s advanced analytics into mymobility, we can further personalize and strengthen our ability to measure what matters most — how patients move in their daily lives — while keeping data capture effortless for patients and low-burden for clinicians.”

The integration supports Zimmer Biomet’s broader connected care strategy, which links technology, data and digital tools across the patient journey. Powered by analysis of more than one million gait cycles every day, OneStep’s mobility intelligence provides one of the world’s largest real-world mobility datasets. By embedding OneStep’s mobility intelligence, Zimmer Biomet enhances its ability to monitor recovery trends, quantify function and support clinicians in tailoring rehabilitation programs with objective, real-world insights.

“Zimmer Biomet has set the standard for digital, connected orthopedic care, and our mobility intelligence is perfectly aligned to their vision,” said Tomer Shussman, CEO of OneStep. “Together, we’re transforming gait and mobility into a vital sign, empowering patients and providers with clinically meaningful data intended to improve outcomes.”¹

The mymobility Care Management Platform provides a guided orthopedic patient experience, including education, surveys, check-ins, messaging, video-guided post-operative exercises, gait and mobility metrics, analytics and telehealth applications — all with automation, data and insights for surgeons to monitor their patients’ recovery process.

iPhone is a registered trademark of Apple, Inc. Android is a trademark of Google LLC.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

About OneStep

OneStep is an FDA-listed, digital care platform that transforms any smartphone into a continuous movement sensor, capturing gait, balance, and mobility data to assess risk, track progress, and personalize care. From fall prevention to orthopedic recovery, cognitive decline to chronic condition monitoring, OneStep brings mobility insights out of the lab and into real life. Because when we can measure how people move, we can change how they’re cared for.” Learn more at www.onestep.co.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

____________________________
¹ Redfern RE, Khan ST, Archibeck MJ, Anderson MB, Piuzzi NS. Establishing Minimal Clinically Important Differences and Substantial Clinical Benefit Thresholds for Various Objective Gait Metrics After Total Knee Arthroplasty. International Society for Technology in Arthroplasty (ISTA) Annual Congress; September 2025; Rome, Italy. Abstract 672.

View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-onestep-collaborate-to-provide-enhanced-mobility-data-to-patients-and-surgeons-to-help-improve-joint-procedure-recovery-302642724.html

SOURCE Zimmer Biomet Holdings, Inc.